RGLS4326 (RG4326) is a first-in-class, short oligonucleotide inhibitor ofmicroRNA-17(miR-17). RGLS4326 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD). RGLS4326 inhibits miR-17 function in HeLa cells with an EC₅₀value of 28.3 nM^[1].

MicroRNA^[1]

RGLS4326, a single-stranded, chemically modified, short oligonucleotide of 9-nt with full complementarity to the miR-17 seed sequence. RGLS4326 inhibits the pathologic functions of the miR-17 family of miRNAs in ADPKD^[1].
RGLS4326 treatment inhibits miR-17 function in kidney collecting duct cells in culture as measured by miR-17 PD-Sig, with an EC₅₀value of 77.2 ± 20.2 nM^[1].
RGLS4326 suppresses the growth of primary human autosomal dominant polycystic kidney disease (ADPKD) cysts^[1].

RGLS4326 preferentially distributes to kidney tubules and cysts. RGLS4326 (a single 30 mg/kg SC injection) is rapidly absorbed into plasma, showing T_maxof ≤1 h, C_maxof 8.5 μg/mL, and half-life of<4 h in wild-type mice^[1].
In vivo administration of RGLS4326 also upregulates the expression of the direct miR-17 target genesPkd1andPkd2^[1].

3082.42

Solid

C₉₅H₁₁₅F₃N₃₂O₅₁P₈S₈

2229964-07-0

Room temperature in continental US; may vary elsewhere.

-20°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)